Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 5/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | GLRA1 | P23415 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (S,R)-Mefloquine SCHEMBL32385911 | 1.00 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 | |
| Mefloquine SCHEMBL7130867 | 1.00 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 | |
| Mefloquine SCHEMBL21782 | 1.00 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 | |
| (S,R)-Mefloquine SCHEMBL21780 | 1.00 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 | |
| Mefloquine SCHEMBL3625982 | 1.00 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 | |
| (S,R)-Mefloquine SCHEMBL16702641 | 1.00 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 | |
| Mefloquine SCHEMBL8575605 | 1.00 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 | |
| (R,R)-Mefloquine SCHEMBL21781 | 1.00 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 | |
| Mefloquine SCHEMBL17087807 | 1.00 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 | |
| Mefloquine SCHEMBL29433990 | 1.00 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3808348-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | Biogen MA Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3025714-B9 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN MA INC (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3025714-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN MA INC (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20110039888-A1 | ASYMMETRIC ALPHA FUNCTIONALIZATION AND ALPHA, ALPHA BISFUNCTIONALIZATION OF ALDEHYDES AND KETONES | COLTART DON M | 2011-02-17 | — | — | US | disclosed |
| US-20110039888-A1 | ASYMMETRIC ALPHA FUNCTIONALIZATION AND ALPHA, ALPHA BISFUNCTIONALIZATION OF ALDEHYDES AND KETONES | COLTART DON M | 2011-02-17 | — | — | US | disclosed |
| WO-2009131657-A1 | ASYMMETRIC ALPHA FUNCTIONALIZATION AND ALPHA, ALPHA BISFUNCTIONALIZATION OF ALDEHYDES AND KETONES | DUKE UNIVERSITY (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20070179123-A1 | Methods and compositions for treating diseases associated with pathogenic proteins | CHIANG PETER K | 2007-08-02 | — | — | US | disclosed |
| US-20070179123-A1 | Methods and compositions for treating diseases associated with pathogenic proteins | CHIANG PETER K | 2007-08-02 | — | — | US | disclosed |
| WO-2007056580-A2 | METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH PATHOGENIC PROTEINS | PHARMADYN, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070078161-A1 | Crystalline forms of (+)- and (-) erythro-mefloquine hydrochloride | SOSEI R&D LTD. (GB) | 2007-04-05 | — | — | US | disclosed |
| US-20070078161-A1 | Crystalline forms of (+)- and (-) erythro-mefloquine hydrochloride | SOSEI R&D LTD. (GB) | 2007-04-05 | — | — | US | disclosed |
| EP-0553778-B1 | Asymmetric hydrogenation | HOFFMANN LA ROCHE (CH) | 2001-12-12 | — | — | EP | disclosed |
| US-5514805-A | ASSYMETRIC HYDROGENATION OF A PYRIDINECARBONYL COMPOUND, RHODIUM PHOSPHINE CATALYST | HOFFMANN-LA ROCHE INC. (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0553778-A1 | Asymmetric hydrogenation | F. HOFFMANN-LA ROCHE AG (CH) | 1993-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039888-A1 | ASYMMETRIC ALPHA FUNCTIONALIZATION AND ALPHA, ALPHA BISFUNCTIONALIZATION OF ALDEHYDES AND KETONES | ALDH3A1, ALDH1A1, ADH1A | KCNH2 1281/4885CYP2D6 924/4885ADORA2A 2396/4885 |
| US-20070179123-A1 | Methods and compositions for treating diseases associated with pathogenic proteins | PRNP, APP, PSEN1 | KCNH2 4124/4885CYP2D6 4061/4885ADORA2A 3182/4885 |
| US-20070078161-A1 | Crystalline forms of (+)- and (-) erythro-mefloquine hydrochloride | YTHDF3, EML4, YTHDF1 | KCNH2 410/4885CYP2D6 250/4885ADORA2A 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.